SPYRE THERAPEUTICS SHARES DOWN 12.4% PREMARKET AFTER CO'S EXPERIMENTAL DRUG FAILS TO MEET THRESHOLD FOR MONOTHERAPY DEVELOPMENT IN RHEUMATOID ARTHRITIS

Reuters · 3d ago

Please log in to view news